Skip to NavigationSkip to content

AZ to rework ongoing immuno-oncology trials to "enhance options"

Published on 17/01/17 at 10:09am

Due to the “strong efficacy” shown by its durvalumab as a treatment for non-small cell lung cancer (NSCLC), AstraZeneca has announced it is to reengineer its clinical trials into the drug in order to “enhance [its] options”, according to company CMO Sean Bohen.

The amendments to its Mystic trial and other related trials investigating durvalumab intend to help explore the firm’s options in first-line NSCLC treatment for a combination of immune-oncology treatments and monotherapy. The Mystic trial was originally designed to evaluate progression-free survival of the drug as a monotherapy and in combination with tremelimumab in patients with PDL1-expressing tumours versus standard-of-care chemotherapy; now redesigned, the trial will also assess overall survival.

First data from the Mystic trial will be released midway through this year, with final results expected sometime in 2018.

Aside from the Mystic trial, the firm is looking to reinforce its regulatory submission of durvalumab in combination with tremelimumab as a first-line NSCLC treatment in China by expanding its Neptune trial in the region with local patients.

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
<